First Quadrant’s Amneal Pharmaceuticals AMRX Stock Holding History

First Quadrant’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$37K	Buy	+8,791	New	+$38.9K	0.21%	59
2018 Q3	–	Sell	-1,036	Closed	-$17K	–	834
2018 Q2	$17K	Buy	+1,036	New	+$18.2K	﹤0.01%	748

Other funds holding AMRX

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Quadrant's AMRX Position: Q1 2022 in Review

First Quadrant opened a new position in Amneal Pharmaceuticals (AMRX) in Q1 2022: 8,791 shares worth $37K. The stake represents 0.21% of the portfolio and ranks #59 among its holdings. This is a return to the name: First Quadrant previously reported a position in AMRX as recently as Q2 2018.

First Quadrant first reported a position in AMRX in Q2 2018 and has held it in 2 quarters since. 168 funds tracked by Wall St. Rank hold AMRX as of Q1 2022.

First Quadrant held 8,791 shares of Amneal Pharmaceuticals worth $37K as of Q1 2022.
Amneal Pharmaceuticals was a new First Quadrant position in Q1 2022.
Amneal Pharmaceuticals made up 0.21% of First Quadrant's portfolio in Q1 2022, its #59 holding.
First Quadrant first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 2 quarters since.
168 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.